Four Taiwan biotech companies to join forces with US partners

This article was published by the Taiwan Headlines on April 4, 2006. It reports that four Taiwanese biotechnology companies recently signed technical cooperation memorandums of understanding with four partners in the United States. These Taiwanese companies will become the production and marking bases of their U.S. partners in Asia.

The four cooperation projects were mediated by Canada's MDS Capital Corp. and the Biotechnology and Pharmaceutical Industries Program Office under Taiwan's Ministry of Economic Affairs. MDS Capital is a leading North American venture capital company that exclusively focuses on providing financial support and other services to emerging life-science companies. The company plans to assist at least 10 foreign companies as they conduct technical transfers to Taiwanese companies in the next five years.

The four Taiwanese companies will receive technical transfers from their U.S. partners. These companies are EMO Biomedicine Corp., Dr. Chip Biotechnology Inc., Biocare Corp., and Genelabs Biotechnology Co., Ltd. Among them, Biocare has already become the contract supplier of its U.S. partner. They will jointly develop the Greater China market. Meanwhile, EMO and its U.S. partner will jointly develop cell-treatment therapy for B-type hepatitis.

Other companies based in the United States and Canada are expected to find partners in Taiwan via MDS Capital's assistance.